Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cost-effectiveness of FDG-PET

This study has been completed.
Sponsor:
Collaborator:
Netherlands: Ministry of Health, Welfare and Sports
Information provided by (Responsible Party):
Juliano Julio Cerci, University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT01438164
First received: September 20, 2011
Last updated: NA
Last verified: September 2011
History: No changes posted
  Purpose

Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.


Condition
Oncologic Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Further study details as provided by University of Sao Paulo:

Enrollment: 500
Study Start Date: June 2005
Study Completion Date: September 2011
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
oncologic patients
initial staging

Detailed Description:

To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

500 oncologic patients

Criteria

Inclusion Criteria:

  • Cancer

Exclusion Criteria:

  • Other malignancy
  • Uncontrolled Diabetes
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Juliano Julio Cerci, Pesquisador executante, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT01438164     History of Changes
Other Study ID Numbers: USP0460/05
Study First Received: September 20, 2011
Last Updated: September 20, 2011
Health Authority: Brazil: Ethics Committee

Keywords provided by University of Sao Paulo:
FDG-PET
cancer
staging
Evaluate the cost impact in the evaluation of oncologic patients.

ClinicalTrials.gov processed this record on November 25, 2014